Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2009

View Archived Issues

Triamcinolone acetonide phase III SCORE study results in macular edema reported

Novo Nordisk to assess insulin analogue NN-1250 in phase III trials in type 1 and 2 diabetes

Inhaled AIR-645 well tolerated in phase I study

Phase II data for p53-SLP vaccine in ovarian cancer reported

BIBF-1120 maintenance therapy may delay disease progression in ovarian cancer

Ono's oral antidiabetic Glactiv tablet approved in Japan

AstraZeneca submits MAA in Europe for Vimovo

FDA approves GSK's cervical cancer vaccine for girls and young women aged 10-25 years

FDA approves Crestor for pediatric heterozygous familial hypercholesterolemia

AstraZeneca and Astellas' Symbicort Turbuhaler approved in Japan for asthma

FDA authorizes Diatherix Laboratories' H1N1-09 influenza test for emergency use

Transgenomic licenses Cold-PCR technology from Dana-Farber Cancer Institute

TcLand Expression starts study of K-RejX test in kidney transplant recipients at risk of CAMR

Med BioGene reports results from validation study of LungExpess Dx in NSCLC

Epigenomics launches Epi proColon diagnostic blood test for colorectal cancer in Europe

Vitae Pharmaceuticals describes 11beta-HSD1 inhibitors for the treatment of diabetes

Novel oncolytic compounds disclosed by Columbia University

Gruenenthal claims ORL1 and mu-opioid receptor ligands for the treatment of pain

Takeda receives Japanese approval for additional indication for Basen

FDA approves Elitek for management of plasma uric acid levels in cancer patients

Rexahn reports topline phase IIa data for Serdaxin in major depressive disorder

K-101 topical solution eradicates infection in adults with distal subungual onychomycosis

Dainippon Sumitomo's Miripla granted Japanese manufacturing and marketing approval

GnRH antagonist elagolix sodium improves endometriosis symptoms in Petal study

Diabetes candidate drug DSP-7238 shows selective and sustained DPP IV inhibition

Patupilone active against breast cancer brain metastases

BNC-210 exhibits anxiolytic and antidepressant activity in preclinical studies in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...